Hualan Biological EngineeringInc Cash Flow Conversion Efficiency
Hualan Biological EngineeringInc cash flow conversion efficiency. Based on the latest financial reports, Hualan Biological EngineeringInc (002007) has a cash flow conversion efficiency ratio of 0.024x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥319.46 Million ≈ $46.75 Million USD) by net assets (CN¥13.25 Billion ≈ $1.94 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Hualan Biological EngineeringInc (2003–2024)
Cash flow conversion efficiency of Hualan Biological EngineeringInc from 2003 to 2024. This chart illustrates how Hualan Biological EngineeringInc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 002007 stock price for real-time trading data and today's change.
Hualan Biological EngineeringInc Cash Flow Conversion Ratio Explained
Hualan Biological EngineeringInc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Hualan Biological EngineeringInc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hualan Biological EngineeringInc ranked by their cash flow conversion efficiency. Also see Hualan Biological EngineeringInc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Genscript Biotech Corporation
F:G51
|
-0.024x |
|
Impinj Inc
NASDAQ:PI
|
0.072x |
|
China Minsheng Banking Corp. Ltd
F:GHFH
|
-0.001x |
|
China Galaxy Securities Co Ltd
F:CGL
|
-0.483x |
|
Ninestar Corp
SHE:002180
|
0.017x |
|
DOF Group ASA
OL:DOFG
|
0.080x |
|
FIT Hon Teng Limited
F:0FJ
|
0.040x |
|
Gentera S.A.B. de C.V
MX:GENTERA
|
0.097x |
Annual Cash Flow Conversion Efficiency for Hualan Biological EngineeringInc (2003–2024)
The table below shows the annual cash flow conversion efficiency of Hualan Biological EngineeringInc from 2003 to 2024. Review 002007 free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥13.85 Billion ≈ $2.03 Billion |
CN¥1.06 Billion ≈ $155.02 Million |
0.077x | -23.71% |
| 2023-12-31 | CN¥13.42 Billion ≈ $1.96 Billion |
CN¥1.35 Billion ≈ $196.94 Million |
0.100x | +27.90% |
| 2022-12-31 | CN¥12.21 Billion ≈ $1.79 Billion |
CN¥957.31 Million ≈ $140.08 Million |
0.078x | -50.39% |
| 2021-12-31 | CN¥9.06 Billion ≈ $1.33 Billion |
CN¥1.43 Billion ≈ $209.62 Million |
0.158x | -3.40% |
| 2020-12-31 | CN¥8.10 Billion ≈ $1.19 Billion |
CN¥1.33 Billion ≈ $193.93 Million |
0.164x | -17.35% |
| 2019-12-31 | CN¥6.88 Billion ≈ $1.01 Billion |
CN¥1.36 Billion ≈ $199.41 Million |
0.198x | -11.60% |
| 2018-12-31 | CN¥5.77 Billion ≈ $844.71 Million |
CN¥1.29 Billion ≈ $189.15 Million |
0.224x | +511.14% |
| 2017-12-31 | CN¥4.84 Billion ≈ $708.55 Million |
CN¥177.42 Million ≈ $25.96 Million |
0.037x | -50.74% |
| 2016-12-31 | CN¥4.44 Billion ≈ $649.04 Million |
CN¥329.94 Million ≈ $48.28 Million |
0.074x | -47.33% |
| 2015-12-31 | CN¥3.88 Billion ≈ $568.41 Million |
CN¥548.62 Million ≈ $80.28 Million |
0.141x | +3.30% |
| 2014-12-31 | CN¥3.64 Billion ≈ $532.05 Million |
CN¥497.15 Million ≈ $72.75 Million |
0.137x | -11.36% |
| 2013-12-31 | CN¥3.31 Billion ≈ $484.47 Million |
CN¥510.70 Million ≈ $74.73 Million |
0.154x | -11.73% |
| 2012-12-31 | CN¥2.83 Billion ≈ $414.24 Million |
CN¥494.69 Million ≈ $72.39 Million |
0.175x | +34.26% |
| 2011-12-31 | CN¥2.58 Billion ≈ $377.67 Million |
CN¥335.93 Million ≈ $49.16 Million |
0.130x | -48.63% |
| 2010-12-31 | CN¥2.41 Billion ≈ $352.04 Million |
CN¥609.53 Million ≈ $89.19 Million |
0.253x | -22.62% |
| 2009-12-31 | CN¥1.86 Billion ≈ $271.60 Million |
CN¥607.73 Million ≈ $88.93 Million |
0.327x | +132.43% |
| 2008-12-31 | CN¥1.14 Billion ≈ $167.42 Million |
CN¥161.18 Million ≈ $23.59 Million |
0.141x | -47.30% |
| 2007-12-31 | CN¥669.71 Million ≈ $98.00 Million |
CN¥179.02 Million ≈ $26.20 Million |
0.267x | +19.65% |
| 2006-12-31 | CN¥588.30 Million ≈ $86.09 Million |
CN¥131.43 Million ≈ $19.23 Million |
0.223x | +25.25% |
| 2005-12-31 | CN¥550.80 Million ≈ $80.60 Million |
CN¥98.24 Million ≈ $14.38 Million |
0.178x | +315.59% |
| 2004-12-31 | CN¥500.48 Million ≈ $73.24 Million |
CN¥21.48 Million ≈ $3.14 Million |
0.043x | +66.40% |
| 2003-12-31 | CN¥129.74 Million ≈ $18.98 Million |
CN¥3.35 Million ≈ $489.64K |
0.026x | -- |
About Hualan Biological EngineeringInc
Hualan Biological Engineering Inc. researches, develops, produces, and commercializes blood products, vaccines, and genetic engineering products in China and internationally. The company offers human serum albumin to treat blood loss trauma, shock caused by burns, intracranial pressure and persistent, liver cirrhosis, and kidney disease; edema for hypoproteinemia, neonatal hyperbilirubinemia, car… Read more